Review Article
Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
Table 1
Characteristics of HCV direct-acting antiviral classes.
| Characteristic | Protease inhibitors | Protease inhibitors | Polymerase inhibitors | Polymerase inhibitors | NS5A inhibitors |
| | First generation | Second generation | Nucleoside analogs | Non-nucleoside analogs | |
| Potency | High Variable among HCV genotypes | High Variable | Moderate Consistent across genotypes | Variable Variable among HCV genotypes | High Multiple HCV genotypes |
| Barrier to resistance | Low | Low | High | Very low | Low |
| PK | Variable qd-tid | qd | qd | Variable qd-tid | qd |
| Adverse event | Rash (SJS, TEN), anemia, hyperbilirubinemia appetite loss, renal toxicity, elevation of uric acid | Anemia hyperbilirubinemia | Mitochondrial nuclear interaction (RBV) | Variable | Variable |
| Drug | Telaprevir Boceprevir | Simeprevir Asunaprevir Faldaprevir | Sofosbuvir Mericitabine | BMS-791325 | Daclatasvir |
| Clinical trial | TVR: ADVANCE [7], ILLUMINATE [8], REALIZE [9] BCV: SPRINT-2 [10], RESPOND-2 [12] | SMV: PILLAR [14], ASPIRE [15] ASV: AI447-011 [16] FDV: SILEN-C2 [17], SOUND-C2 [18, 19] | SOF: ATOMIC [20], ELECTRON [21] MRB: JUMP-C [22], INFORM-1 [23], INFORM-SVR [24] | | DCT: AI447-011 [25] |
| Comments | | Better barrier, pan-genotypic | Single target active site | Allosteric, many targets | Multiple antiviral mechanisms of action |
|
|
PK: pharmacokinetics; qd: once a day; tid: three times a day; RBV: ribavirin. Modified from [1]. SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; TVR: telaprevir; BCV: boceprevir; SMV: simeprevir; ASV: asunaprevir; FDV: faldaprevir; SOF: sofosbuvir; MRB: mericitabine; DCV: daclatasvir.
|